clinical trial · NCT07075718
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
GlaucomaGen 2 Travoprost Intracameral ImplantTimolol eye drops 0.5%Sham ProcedurePlacebo eye drops
brief summary
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
started
Jun 12, 2025
primary completion
Mar 1, 2028
completion
Mar 1, 2032
last updated
Mar 2, 2026
detailed description
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Compared to Timolol Ophthalmic Solution 0.5% Administered Twice Daily in Subjects with Open-Angle Glaucoma or Ocular Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol